改进的紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的临床观察(1)
 |
| 第1页 |
参见附件(1876KB，3页)。
【摘要】 目的 为比较紫杉醇联合顺铂改进的3 周方案与传统 3 周方案治疗晚期NSCLC的疗效、毒副反应及 1 年生存率。方法 75例经组织学或细胞学确诊的Ⅲb或Ⅳ期NSCLC患者,随机分为两组,分别接受改进方案 (A组) 和传统3 周方案 (B组) 化疗。2周期后 评价疗效与毒副反应,并随访 l 年生存率。结果 A组无CR,A组总有效率为47.9% (18/37),;B组 CR 1例,总有效率为52.6% (20/38)。总有效率两组差异无显著性(P>0.05),两组1年生存率分别为38.2%和35.6%。两组差异无显著性(P>0.05)。主要毒副反应为恶心、呕吐、骨髓抑制、脱发、周围神经毒性、肝功能受损、心脏毒性等。A、B组差异无显著性(P>0.05)。关节肌肉疼痛 A组 32.4%;B组84.2%,两组差异有显著性(P<0.05)。结论 紫杉醇联合顺铂改进的3周方案治疗NSCLC与传统3周方案相比,疗效相似,但血液学毒性明显下降,耐受性好。
【关键词】 非小细胞肺癌;紫杉醇;顺铂;化疗
Clinical analysis of modified paclitaxel combined cisplatin as chemotherapy for advanced non-small cell lung cancer
HAN Wen-jie.
Third department of oncology, Shangqiu the first people’s hospital, Henan,Shangqiu476001,China
【Abstract】 Objective To compare the effect and toxic of modified and standard3 -weeks’ paclitaxel / cisplatin as first line chemotherapy for advanced NSCLC. Methods 75 patients with stage Ⅲb or Ⅳ NSCLC (proven by histology or cytology ) were randomly divided into two groups, modified (A)and standard(B) chemotherapy. The effect and toxicity were assessed after two cycles and one-year survival rate was followed up.Results There was no CR in A groups.The overall response rate was 47.9%;There was 1 CR in B groups. the overall response rate was 52.6%. The one -year survival rate were 38.2%and 35.6%in group A and B, respectively. There were no significant difference about the overall response rate (P>0.05)and one-year survival rate(P>0.05) between group A and B.The major adverse reaction were nausea, emesia, myelosuppression, alopecie, peripheral nerve neurotoxicity, Hepatic function damage, cordis-toxicity. There were no significant difference about the overall response rate (P>0.05) between group A and B.The syntaxis and muscle pain were 32.4%and 84.2%in group A and B, respectively. There were significant difference about the overall response rate (P<0.05) between group A and B.Conclusion In comparison with the standard 3-weeks’ paclitaxel / cisplatin chemotherapy, the modified one has similar response rate but lower hematologic toxicity and thus it is wel1 tolerated ......
您现在查看是摘要介绍页，详见PDF附件(1876KB，3页)。